Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update October 8, 2024 • 7:00 AM EDT
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 September 20, 2024 • 9:25 AM EDT
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences September 18, 2024 • 8:30 AM EDT
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study September 11, 2024 • 8:30 AM EDT
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. September 9, 2024 • 8:30 AM EDT
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer August 19, 2024 • 9:00 AM EDT
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor July 8, 2024 • 6:30 AM EDT
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones July 1, 2024 • 8:35 AM EDT
TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) June 3, 2024 • 8:35 AM EDT
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results May 14, 2024 • 4:45 PM EDT